More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$464043379
EPS
-0.13
P/E ratio
--
Price to sales
1.92
Dividend yield
--
Beta
1.169334
Previous close
$3.18
Today's open
$3.18
Day's range
$3.11 - $3.23
52 week range
$3.03 - $7.51
show more
CEO
Joseph H. Capper
Employees
808
Headquarters
Marietta, GA
Exchange
NASDAQ Capital Market
Shares outstanding
145925591
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
MiMedx Group Bets on Surgery Growth and Sanara Deal as Wound Care Struggles
MiMedx Group NASDAQ: MDXG is counting on growth in its surgical business and its pending acquisition of Sanara MedTech to help offset a difficult year for its wound care franchise, Chief Financial Officer Doug Rice said at the Canaccord Genuity MedTech and Diagnostics Conference.
MarketBeat • Nov 16, 2026

MIMEDX to Participate in Upcoming Investor Conferences
MARIETTA, Ga., Nov. 06, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:
GlobeNewsWire • Nov 6, 2026

What MiMedx Group (MDXG) Said on Its Q3 Earnings Call
MiMedx Group NASDAQ: MDXG reported third-quarter net sales of $62 million, down 45% from a year earlier, as continued disruption in the wound care market offset growth in its surgical business. The company said surgical revenue rose 9% year over year to $40 million, while wound care revenue declined 71% to $22 million following Medicare reimbursement changes that took effect at the beginning of 2026.
MarketBeat • Oct 29, 2026

MiMedx Group, Inc. (MDXG) Q3 2026 Earnings Call Transcript
MiMedx Group, Inc. (MDXG) Q3 2026 Earnings Call Transcript
Seeking Alpha • Oct 28, 2026

MIMEDX Announces Third Quarter 2026 Operating & Financial Results
Reports Continued Double-Digit Year-Over-Year Volume Growth for Surgical Franchise Delivers Wound Care Center Volume Growth Both Sequentially and Year-Over-Year Obtained Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter During Quarter Today Announced Patent License Agreement, Underscoring Strength of IP Portfolio Management to Host Conference Call Today, October 28, 2026, at 4:30 PM ET MARIETTA, Ga., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced operating and financial results for the third quarter of 2026.
GlobeNewsWire • Oct 28, 2026

MIMEDX Announces $25 Million Patent License Agreement
MARIETTA, Ga., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into a license agreement with a wound care competitor that resolves allegations of infringement of MIMEDX's patents.
GlobeNewsWire • Oct 28, 2026

MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026
MARIETTA, Ga., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, October 28, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.
GlobeNewsWire • Oct 14, 2026

MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter
Court Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified as a Biological Product
GlobeNewsWire • Sep 23, 2026

Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sanara MedTech Inc. (NasdaqCM: SMTI) to MiMedx Group, Inc. (NasdaqCM: MDXG). Under the terms of the proposed transaction, shareholders of Sanara will receive $33.00 in cash and 0.4735 shares of MiMedx common stock for each share of Sanara that they own. KSF is seeking to determine whether this consi.
Business Wire • Sep 10, 2026

MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript
MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript
Seeking Alpha • Jul 30, 2026

¹ Disclosures

Open an M1 investment account to buy and sell MiMedx Group Inc commission-free¹. Build wealth for the long term using automated trading and transfers.